Systemic sclerosis & Raynaud's
Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy
Authors' conclusion
MMF and rituximab compared with AHSCT in SSc patients eligible for AHSCT resulted in similar skin and lung clinical improvement with a better safety profile at 24 months.
Study context
- Population
- Patients with early diffuse progressive SSc eligible for autologous hematopoietic stem cell transplantation (AHSCT)
- Exposure
- MMF plus rituximab combination therapy vs AHSCT
- Combinationn = Twenty-one
- AHSCTn = 16reference
- Outcome
- Clinical improvement (mRSS decrease >25% or FVC increase >10%)
- Follow-up
- 12 months
Main finding
As reported in the abstract
P = 0.7
Observational data: associations, not effects.
Further findings
| Outcome | HR | P value |
|---|---|---|
| EFS (absence of persistent major organ failure or death) · up to 24 monthsFavoured the combination group | 0.09 | P = 0.04 |
Modified Rodnan Skin Score (mRSS) and forced vital capacity (FVC) over follow-up · up to 24 months
- Both groups had a significant and comparable reduction in mRSS and increase in FVC at each time interval
Original publication
Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy. Rheumatology (Oxford). Published 6 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →